Please Wait
Applying Filters...
menu
    • menu
    Seqens CDMO-PSE
    News
    SEQENS Unit Joins Smart Immune for Clinical Batch Making

    03 Dec 2024

    // PRESS RELEASE

    Arkema Grants PEKK Tech License To SEQENS For Manufacturing

    25 Jun 2024

    // PRESS RELEASE

    Novartis sells France CGT biz to Seqens

    19 Dec 2023

    // BIOPROCESSINTEL

    Data Compilation
    #PharmaFlow

    Seqens 250x250

    Contact Supplier

    Website

    USCC

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
    Left Arrow
    Right Arrow
    Related CompaniesRelated Companies

    About

    Three custom development and manufacturing organizations – PCAS S.A. in France, Chemie Uetikon in Germany and PCI Synthesis in the United States – have joined forces as Seqens CDMO (formerly Novacap) to offer world-class Drug Substance Development and Manufacturing services to the pharmaceutical industry. With three R&D centers, six cGMP / FDA inspected production sites in Europe and the United States supported by two manufacturing sites for production of critical intermediates & Regulatory Starting Materials (RSMs), the group offers a manufacturing network capable to embrace complexity in developing, industrializing & manufacturing.